NCT04311424

Study of Tirzepatide in Healthy Participants

Disposition of [14C]-Tirzepatide Following Subcutaneous Administration in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Male
• Age: 30 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to look at how much tirzepatide gets into the bloodstream and how long the body takes to get rid of it. This study will involve a single dose of 14C radiolabelled tirzepatide. This means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 15 weeks, including screening.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	14C Tirzepatide	Administered SC.

Timeline

• Start date: 2020-07-28
• Primary completion: 2020-10-02
• Completion: 2020-10-02
• First posted: 2020-03-17
• Last updated: 2023-03-24
• Results posted: 2023-03-24

Locations

1 site across 1 country: United Kingdom